{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:02:19Z","timestamp":1761393739053},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,11,12]],"date-time":"2008-11-12T00:00:00Z","timestamp":1226448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s12032-008-9126-3","type":"journal-article","created":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T11:25:03Z","timestamp":1226402703000},"page":"335-343","source":"Crossref","is-referenced-by-count":1,"title":["Triple negative breast cancer compared to hormone receptor negative\/HER2 positive breast cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Irfan","family":"Cicin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Karagol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ufuk","family":"Usta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atakan","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sernaz","family":"Uzunoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rusen","family":"Alas-Cosar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarkan","family":"Yetisyigit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazim","family":"Uygun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,12]]},"reference":[{"key":"9126_CR1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","volume":"18","author":"J Ferlay","year":"2007","unstructured":"Ferlay J, et al. Estimates of the Cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581\u201392. doi: 10.1093\/annonc\/mdl498 .","journal-title":"Ann Oncol"},{"key":"9126_CR2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, et al. Cancer Statistics, 2007. CA Cancer J Clin. 2007;57:43\u201366.","journal-title":"CA Cancer J Clin"},{"key":"9126_CR3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","volume":"356","author":"PM Ravdin","year":"2007","unstructured":"Ravdin PM, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670\u20134. doi: 10.1056\/NEJMsr070105 .","journal-title":"N Engl J Med"},{"key":"9126_CR4","doi-asserted-by":"crossref","unstructured":"Cinieri S, et al. Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St. Gailen International Expert Consensus Conference. Ann Oncol. 2007;18 Suppl 6:63\u20135. doi: 10.1093\/annonc\/mdm227 .","DOI":"10.1093\/annonc\/mdm227"},{"key":"9126_CR5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","volume":"8","author":"S Cleator","year":"2007","unstructured":"Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235\u201344. doi: 10.1016\/S1470-2045(07)70074-8 .","journal-title":"Lancet Oncol"},{"key":"9126_CR6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.humpath.2007.06.012","volume":"39","author":"H Liu","year":"2008","unstructured":"Liu H, et al. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol. 2008;39:167\u201374. doi: 10.1016\/j.humpath.2007.06.012 .","journal-title":"Hum Pathol"},{"key":"9126_CR7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.humpath.2006.04.015","volume":"37","author":"MJ Kim","year":"2006","unstructured":"Kim MJ, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2\/neu-overexpressing phenotypes. Hum Pathol. 2006;37:1217\u201326. doi: 10.1016\/j.humpath.2006.04.015 .","journal-title":"Hum Pathol"},{"key":"9126_CR8","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006;295:2492\u2013502. doi: 10.1001\/jama.295.21.2492 .","journal-title":"JAMA"},{"key":"9126_CR9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cncr.23243","volume":"112","author":"M Brown","year":"2008","unstructured":"Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999\u20132004. Cancer. 2008;112:737\u201347. doi: 10.1002\/cncr.23243 .","journal-title":"Cancer"},{"key":"9126_CR10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jcp.2003.007724","volume":"57","author":"IO llis","year":"2004","unstructured":"llis IO, et al. Updated recommendations for her-2 testing in the UK. J Clin Pathol. 2004;57:233\u20137.","journal-title":"J Clin Pathol"},{"key":"9126_CR11","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC cancer staging manual","author":"FL Greene","year":"2002","unstructured":"Greene FL, et al. AJCC cancer staging manual. 6th ed. New York (NY): Springer-Verlag; 2002.","edition":"6"},{"key":"9126_CR12","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.onc.1210014","volume":"26","author":"NC Turner","year":"2007","unstructured":"Turner NC, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26:2126\u201332. doi: 10.1038\/sj.onc.1210014 .","journal-title":"Oncogene"},{"key":"9126_CR13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/jnci\/djh312","volume":"96","author":"RD Kennedy","year":"2004","unstructured":"Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96:1659\u201368.","journal-title":"J Natl Cancer Inst"},{"key":"9126_CR14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1309\/YMJ3A83TB39MRUT9","volume":"123","author":"P Lal","year":"2005","unstructured":"Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3, 655 invasive breast carcinomas. Am J Clin Pathol. 2005;123:541\u20136. doi: 10.1309\/YMJ3A83TB39MRUT9 .","journal-title":"Am J Clin Pathol"},{"key":"9126_CR15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","volume":"9","author":"M Cianfrocca","year":"2004","unstructured":"Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606\u201316. doi: 10.1634\/theoncologist.9-6-606 .","journal-title":"Oncologist"},{"key":"9126_CR16","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","volume":"22","author":"NU Lin","year":"2004","unstructured":"Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608\u201317. doi: 10.1200\/JCO.2004.01.175 .","journal-title":"J Clin Oncol"},{"key":"9126_CR17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10549-005-0323-x","volume":"91","author":"M Ryberg","year":"2005","unstructured":"Ryberg M, et al. Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat. 2005;91:217\u201325. doi: 10.1007\/s10549-005-0323-x .","journal-title":"Breast Cancer Res Treat"},{"key":"9126_CR18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/cncr.22041","volume":"107","author":"YL Tham","year":"2006","unstructured":"Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006;107:696\u2013704. doi: 10.1002\/cncr.22041 .","journal-title":"Cancer"},{"key":"9126_CR19","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1200\/JCO.2006.07.0250","volume":"24","author":"Z Gabos","year":"2006","unstructured":"Gabos Z, et al. Prognostic signif\u0131cance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24:5658\u201363. doi: 10.1200\/JCO.2006.07.0250 .","journal-title":"J Clin Oncol"},{"key":"9126_CR20","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/0008-5472.CAN-06-3316","volume":"67","author":"D Palmieri","year":"2007","unstructured":"Palmieri D, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007;67:4190\u20138. doi: 10.1158\/0008-5472.CAN-06-3316 .","journal-title":"Cancer Res"},{"key":"9126_CR21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1634\/theoncologist.12-7-766","volume":"12","author":"S Gori","year":"2007","unstructured":"Gori S, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist. 2007;12:766\u201373. doi: 10.1634\/theoncologist.12-7-766 .","journal-title":"Oncologist"},{"key":"9126_CR22","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/bcr1870","volume":"10","author":"BH Nam","year":"2008","unstructured":"Nam BH, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008;10:R20. doi: 10.1186\/bcr1870 .","journal-title":"Breast Cancer Res"},{"key":"9126_CR23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jcp.2005.033043","volume":"59","author":"S Banerjee","year":"2006","unstructured":"Banerjee S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59:729\u201335. doi: 10.1136\/jcp.2005.033043 .","journal-title":"J Clin Pathol"},{"key":"9126_CR24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/jnci\/87.9.682","volume":"87","author":"CM Tsai","year":"1995","unstructured":"Tsai CM, et al. Enhanced chemoresistance by elevation of the level of p185neu in HER-2\/neu transfected human lung cancer cells. J Natl Cancer Inst. 1995;87:682\u20134. doi: 10.1093\/jnci\/87.9.682 .","journal-title":"J Natl Cancer Inst"},{"key":"9126_CR25","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1038\/sj.onc.1203972","volume":"19","author":"D Yu","year":"2000","unstructured":"Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000;19:6115\u201321. doi: 10.1038\/sj.onc.1203972 .","journal-title":"Oncogene"},{"key":"9126_CR26","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa054504","volume":"354","author":"KI Pritchard","year":"2006","unstructured":"Pritchard KI, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006;354:2103\u201311. doi: 10.1056\/NEJMoa054504 .","journal-title":"N Engl J Med"},{"key":"9126_CR27","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMoa071167","volume":"357","author":"DF Hayes","year":"2007","unstructured":"Hayes DF, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357:1496\u2013506. doi: 10.1056\/NEJMoa071167 .","journal-title":"N Engl J Med"},{"key":"9126_CR28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1368-7646(03)00040-2","volume":"6","author":"JS Chen","year":"2003","unstructured":"Chen JS, Lan K, Hung MC. Strategies to target HER2\/neu overexpression for Cancer therapy. Drug Resist Updat. 2003;6:129\u201336. doi: 10.1016\/S1368-7646(03)00040-2 .","journal-title":"Drug Resist Updat"},{"key":"9126_CR29","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659\u201372. doi: 10.1056\/NEJMoa052306 .","journal-title":"N Engl J Med"},{"key":"9126_CR30","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673\u201384. doi: 10.1056\/NEJMoa052122 .","journal-title":"N Engl J Med"},{"key":"9126_CR31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39\u201351. doi: 10.1056\/NEJMra043186 .","journal-title":"N Engl J Med"},{"key":"9126_CR32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cncr.22885","volume":"110","author":"HJ Burstein","year":"2007","unstructured":"Burstein HJ, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007;110:965\u201372. doi: 10.1002\/cncr.22885 .","journal-title":"Cancer"},{"key":"9126_CR33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235:177\u201382. doi: 10.1126\/science.3798106 .","journal-title":"Science"},{"key":"9126_CR34","first-page":"4322","volume":"50","author":"A Borg","year":"1990","unstructured":"Borg A, et al. HER-2\/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4322\u20137.","journal-title":"Cancer Res"},{"key":"9126_CR35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/bjc.1991.103","volume":"63","author":"J Winstanley","year":"1991","unstructured":"Winstanley J, et al. The long term prognostic significance of c-erb-2 in primary breast cancer. Br J Cancer. 1991;63:447\u201350.","journal-title":"Br J Cancer"},{"key":"9126_CR36","first-page":"566","volume":"51","author":"MC Paterson","year":"1991","unstructured":"Paterson MC, et al. Correlation between c-erb-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51:566\u20137.","journal-title":"Cancer Res"},{"key":"9126_CR37","first-page":"944","volume":"51","author":"GM Clark","year":"1991","unstructured":"Clark GM, McGuire WL. Follow-up study of HER-2\/neu amplification in primary breast cancer. Cancer Res. 1991;51:944\u20138.","journal-title":"Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9126-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-008-9126-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9126-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T22:22:36Z","timestamp":1559427756000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-008-9126-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,12]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["9126"],"URL":"https:\/\/doi.org\/10.1007\/s12032-008-9126-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,12]]}}}